EG24076A - Mesylate dihydrate salts of 5-(2-4(1,2 benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one - Google Patents

Mesylate dihydrate salts of 5-(2-4(1,2 benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one

Info

Publication number
EG24076A
EG24076A EG37997A EG37997A EG24076A EG 24076 A EG24076 A EG 24076A EG 37997 A EG37997 A EG 37997A EG 37997 A EG37997 A EG 37997A EG 24076 A EG24076 A EG 24076A
Authority
EG
Egypt
Prior art keywords
benzisothiazol
indol
piperazinyl
dihydro
chloro
Prior art date
Application number
EG37997A
Other languages
English (en)
Inventor
Frank R Busch
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of EG24076A publication Critical patent/EG24076A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Saccharide Compounds (AREA)
EG37997A 1996-05-07 1997-05-04 Mesylate dihydrate salts of 5-(2-4(1,2 benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one EG24076A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US1675796P 1996-05-07 1996-05-07

Publications (1)

Publication Number Publication Date
EG24076A true EG24076A (en) 2008-05-11

Family

ID=21778804

Family Applications (1)

Application Number Title Priority Date Filing Date
EG37997A EG24076A (en) 1996-05-07 1997-05-04 Mesylate dihydrate salts of 5-(2-4(1,2 benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one

Country Status (40)

Country Link
US (1) US6245765B1 (cg-RX-API-DMAC7.html)
EP (1) EP0918772B1 (cg-RX-API-DMAC7.html)
JP (1) JP3494659B2 (cg-RX-API-DMAC7.html)
KR (1) KR100333215B1 (cg-RX-API-DMAC7.html)
CN (1) CN1091769C (cg-RX-API-DMAC7.html)
AP (1) AP765A (cg-RX-API-DMAC7.html)
AR (1) AR007004A1 (cg-RX-API-DMAC7.html)
AT (1) ATE278689T1 (cg-RX-API-DMAC7.html)
AU (1) AU731267B2 (cg-RX-API-DMAC7.html)
BG (1) BG63544B1 (cg-RX-API-DMAC7.html)
BR (1) BR9709889A (cg-RX-API-DMAC7.html)
CA (1) CA2252898C (cg-RX-API-DMAC7.html)
CO (1) CO4940466A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ289215B6 (cg-RX-API-DMAC7.html)
DE (1) DE69731094T2 (cg-RX-API-DMAC7.html)
DK (1) DK0918772T3 (cg-RX-API-DMAC7.html)
DZ (1) DZ2222A1 (cg-RX-API-DMAC7.html)
EA (1) EA001190B1 (cg-RX-API-DMAC7.html)
EG (1) EG24076A (cg-RX-API-DMAC7.html)
ES (1) ES2229342T3 (cg-RX-API-DMAC7.html)
GT (1) GT199700052A (cg-RX-API-DMAC7.html)
HR (1) HRP970236B1 (cg-RX-API-DMAC7.html)
ID (1) ID16867A (cg-RX-API-DMAC7.html)
IL (1) IL126591A (cg-RX-API-DMAC7.html)
IS (1) IS2080B (cg-RX-API-DMAC7.html)
MA (1) MA24171A1 (cg-RX-API-DMAC7.html)
MY (1) MY119997A (cg-RX-API-DMAC7.html)
NO (1) NO312514B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ332218A (cg-RX-API-DMAC7.html)
OA (1) OA10909A (cg-RX-API-DMAC7.html)
PL (1) PL188330B1 (cg-RX-API-DMAC7.html)
PT (1) PT918772E (cg-RX-API-DMAC7.html)
SI (1) SI0918772T1 (cg-RX-API-DMAC7.html)
SK (1) SK282837B6 (cg-RX-API-DMAC7.html)
TN (1) TNSN97074A1 (cg-RX-API-DMAC7.html)
TR (1) TR199802240T2 (cg-RX-API-DMAC7.html)
TW (1) TW491847B (cg-RX-API-DMAC7.html)
UA (1) UA46840C2 (cg-RX-API-DMAC7.html)
WO (1) WO1997042191A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA973876B (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127497A (en) * 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
NZ551012A (en) * 2000-06-02 2008-04-30 Pfizer Prod Inc Use of S-methyl-dihydro-ziprasidone administered via either the oral, parenteral (such as subcutaneous, intravenous, intramuscular, intrasternal and infusion techniques), rectal, intranasal or topical routes in doses ranging from 0.5 to 500 mg per day
UY27668A1 (es) 2002-02-20 2003-10-31 Pfizer Prod Inc Composición de ziprasidona y controles sintéticos
US20040048876A1 (en) * 2002-02-20 2004-03-11 Pfizer Inc. Ziprasidone composition and synthetic controls
AU2004237951A1 (en) 2003-05-16 2004-11-25 Pfizer Products Inc. Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines
EP1530570A2 (en) * 2003-06-03 2005-05-18 Teva Pharmaceutical Industries Limited CRISTALLINE ZIPRASIDONE HCl AND PROCESSES FOR PREPARATION THEREOF
EP1628973A2 (en) 2003-10-24 2006-03-01 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
BRPI0510942A (pt) * 2004-05-11 2007-07-17 Pfizer Prod Inc combinação de antipsicóticos atìpicos e antagonistas do receptor 5-ht1b
CA2467538C (en) 2004-05-14 2010-08-24 Apotex Pharmachem Inc. New amorphous ziprasidone hydrochloride (5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride) and processes to produce the same
CA2471219A1 (en) 2004-06-14 2005-12-14 Apotex Pharmachem Inc. Improved preparation of an anhydrate form of 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one hydrochloride (ziprasidone hydrochloride)
US7777037B2 (en) * 2004-10-27 2010-08-17 Dr. Reddy's Laboratories Limited Ziprasidone process
CA2587710C (en) * 2004-11-16 2014-10-21 Elan Pharma International Ltd. Injectable nanoparticulate olanzapine formulations
CA2591670A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Process of preparing ziprasidone mesylate
WO2006086779A1 (en) * 2005-02-11 2006-08-17 Teva Pharmaceutical Industries Ltd. Amorphous ziprasidone mesylate
US20080254114A1 (en) * 2005-03-03 2008-10-16 Elan Corporation Plc Controlled Release Compositions Comprising Heterocyclic Amide Derivative Nanoparticles
ITMI20050346A1 (it) 2005-03-07 2006-09-08 Dipharma Spa Forma solida di ziprasidone cloridrato
CA2500667C (en) 2005-03-11 2013-01-15 Apotex Pharmachem Inc. Preparation of acid addition salts of ziprasidone and intermediates thereof by solid phase-gas phase reactions
WO2006098834A2 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Crystalline forms of ziprasidone mesylate
WO2006099452A1 (en) * 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Anhydrous ziprasidone mesylate and a process for its preparation
ITMI20052216A1 (it) * 2005-11-18 2007-05-19 Dipharma Spa Procedimento per la preparazione di ziprasidone
WO2008143960A1 (en) * 2007-05-18 2008-11-27 Scidose Llc Ziprasidone formulations
WO2009156889A1 (en) * 2008-06-25 2009-12-30 Pfizer Inc. Diaryl compounds and uses thereof
JP5893616B2 (ja) * 2010-10-18 2016-03-23 大日本住友製薬株式会社 注射用徐放性製剤
SI23610A (sl) 2011-01-13 2012-07-31 Diagen@d@o@o Nove adicijske soli ziprasidona postopek za njihovo pripravo in njihova uporaba v terapiji
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX173362B (es) * 1987-03-02 1994-02-23 Pfizer Compuestos de piperazinil heterociclicos y procedimiento para su preparacion
US4831031A (en) * 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5206366A (en) * 1992-08-26 1993-04-27 Pfizer Inc. Process for preparing aryl piperazinyl-heterocyclic compounds
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US5359068A (en) 1993-06-28 1994-10-25 Pfizer Inc. Processes and intermediates for the preparation of 5-[2-(4-(benzoisothiazol-3-yl)-piperazin-1-yl)ethyl]-6-chloro-1,3-dihydro-indol-2-one
CZ289216B6 (cs) 1996-05-07 2001-12-12 Pfizer Inc. Trihydrát methansulfonátu 5-(2-(4-(1,2-benzizothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor-1,3-dihydro-2H-indol-2-onu, farmaceutická kompozice a léčivo na jeho bázi

Also Published As

Publication number Publication date
EP0918772A1 (en) 1999-06-02
AU731267B2 (en) 2001-03-29
JP3494659B2 (ja) 2004-02-09
GT199700052A (es) 2001-08-29
CN1216991A (zh) 1999-05-19
CO4940466A1 (es) 2000-07-24
DK0918772T3 (da) 2005-01-10
MA24171A1 (fr) 1997-12-31
IS2080B (is) 2006-02-15
KR20000010824A (ko) 2000-02-25
OA10909A (en) 2001-10-26
NO312514B1 (no) 2002-05-21
PT918772E (pt) 2004-12-31
CZ349398A3 (cs) 1999-09-15
WO1997042191A1 (en) 1997-11-13
AU2174797A (en) 1997-11-26
BR9709889A (pt) 1999-08-10
DZ2222A1 (fr) 2002-12-03
HK1017892A1 (en) 1999-12-03
IL126591A0 (en) 1999-08-17
SK282837B6 (sk) 2002-12-03
CZ289215B6 (cs) 2001-12-12
SK150898A3 (en) 2000-02-14
CN1091769C (zh) 2002-10-02
EA001190B1 (ru) 2000-12-25
AR007004A1 (es) 1999-10-13
NO985194L (no) 1998-11-06
PL188330B1 (pl) 2005-01-31
TW491847B (en) 2002-06-21
DE69731094T2 (de) 2006-02-23
AP765A (en) 1999-09-17
CA2252898A1 (en) 1997-11-13
US6245765B1 (en) 2001-06-12
EP0918772B1 (en) 2004-10-06
PL329884A1 (en) 1999-04-12
JPH11509867A (ja) 1999-08-31
SI0918772T1 (en) 2005-02-28
KR100333215B1 (ko) 2002-06-20
TNSN97074A1 (fr) 2005-03-15
DE69731094D1 (de) 2004-11-11
NZ332218A (en) 2005-02-25
IS4874A (is) 1998-10-20
IL126591A (en) 2001-11-25
MY119997A (en) 2005-08-30
ATE278689T1 (de) 2004-10-15
ZA973876B (en) 1998-11-06
AP9700976A0 (en) 1997-07-31
ES2229342T3 (es) 2005-04-16
CA2252898C (en) 2003-04-08
EA199800912A1 (ru) 1999-04-29
NO985194D0 (no) 1998-11-06
ID16867A (id) 1997-11-20
HRP970236B1 (en) 2002-12-31
TR199802240T2 (cg-RX-API-DMAC7.html) 1999-02-22
HRP970236A2 (en) 1998-06-30
BG102892A (en) 1999-09-30
BG63544B1 (bg) 2002-04-30
UA46840C2 (uk) 2002-06-17

Similar Documents

Publication Publication Date Title
EG24076A (en) Mesylate dihydrate salts of 5-(2-4(1,2 benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
EG24401A (en) Mesylate. Trihydrate of. 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-ine
AU4600493A (en) Monohydrate of 5-(2-(4-(1,2 benzisothiazol-3-yl) -1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one hydrochloride
PL334218A1 (en) Derivatives of 2-(purin-9-yl)-tetrahydrofurane 3,4-diole
HUP0104646A3 (en) Fused 1,2,4-thiadiazine derivatives, their preparation and use
HUP0101475A3 (en) 4,5,6 and 7-indole and indoline derivatives, their preparation and use
FR14C0044I2 (fr) Derives de 3-(2-oxo- 1,3']bipyrrolidinyl-3-ylidenemethyl)-cephemes
FR2767677B1 (fr) Microkeratome pour chirurgie optalmologique
IL133960A0 (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-1h-indole derivatives
ATE266637T1 (de) 3,3-biarylpiperidin- und 3,3- biarylmorpholinderivate
IL137518A0 (en) Derivatives of 1,2,4-oxadiazolone
HU9202914D0 (en) 4-(4-(4-hydroxiphenyl)-1-piperazinyl)-5-methyl-3h-1,2,4-triazole-3-one derivatives
HUP0003758A3 (en) 2-substituted 1,2-benzisothiazole derivatives and their use as serotonin antagonists (5-ht1a, 5-ht1b and 5-ht1d)
IL139962A0 (en) 4,5,6 and 7-indole and indoline derivatives, their preparation and use
GB9706730D0 (en) 2-[(3-substituted)-5-Isoxazolymethylaminojalkanamid derivatives
GB9714303D0 (en) 5-(3-phenyl-3-oxo-propyl)-1H-tetrazole derivatives
ZA200003926B (en) Topiramate and related derivatives for treating Schizophrenia.
NZ300041A (en) 2-(2,3,5,6-tetrafluoropyridin-4-yl)-1,2,5-thiazolidin-3-one 1,1-dioxide derivatives
NZ301453A (en) 4-(substituted phenyl),4-(substituted carboxyl, carboxylamide or alkyl)-cyclohexan-1-one derivatives and medicaments
HUP9802876A3 (en) Process for producing 2-(methylsulfonyl)-5-(trifluoromethyl)-1,3,4-thiadiazole
AU3632099A (en) Biologically active 2-r-5-amino-1,3,4-thiadiazole derivatives
AU1970800A (en) 1,4-benzodiazepinone derivatives and their use as integrin antagonists
GB9817996D0 (en) Tissue paper I
NO996392D0 (no) Angiogenese-inhiberende 5-substituerte-1,2,4-tiadiazolyl- derivater
GB9610963D0 (en) 2-[(3-substituted)-5-isoxazolymethylamino]alkanamide derivatives